
MedImmune is a biotechnology company that has made significant contributions to the field of medicine. It was founded in 1988 by S. Lawrence Zipursky.
MedImmune has been at the forefront of developing vaccines and treatments for various diseases. One of its most notable achievements is the development of the flu vaccine, FluMist.
If this caught your attention, see: Mirati Therapeutics
Recent Developments
MedImmune has made significant strides in developing treatments for respiratory diseases, including a phase III clinical trial for its candidate, Respimun.
The company has also expanded its research into infectious diseases, such as a partnership with the National Institutes of Health to develop a vaccine against the H7N9 flu virus.
MedImmune has a strong pipeline of products in various stages of development, with several candidates in phase II and III clinical trials.
The company's commitment to innovation and collaboration has led to the development of several new treatments, including its candidate for respiratory syncytial virus (RSV) infection, which has shown promising results in clinical trials.
Check this out: Samuel Israel III
Frequently Asked Questions
What is the stock symbol for MedImmune?
The stock symbol for MedImmune is MM or MEDI. This symbol is used to identify the company's stock on various financial platforms.
Featured Images: pexels.com

